Hospital & Healthcare Services · Founded 1982 · www.kauveryhospital.com · BSE 524520 · NSE KMC SHIL · ISIN INE879K01018
No Notes Added Yet
Business
KMC Speciality Hospitals (India) Ltd. operates as a healthcare provider in India, primarily focusing on specialty hospital services. The company offers a range of medical services including in-patient and out-patient care, diagnostic services, emergency services, and various surgical procedures across multiple medical disciplines. Its core business model revolves around providing comprehensive, high-quality healthcare to patients through its hospital facilities. The company generates revenue through fees charged for consultations, medical procedures, surgeries, room charges, diagnostic tests, and pharmacy sales.
Revenue Mix
While specific revenue percentages are not provided, typical revenue segments for a multi-speciality hospital like KMC would include:
In-patient services: This usually constitutes the largest portion of revenue, including room charges, surgical fees, treatment costs, and intensive care.
Out-patient services: Consultations, minor procedures, and follow-up visits.
Diagnostic services: Lab tests, radiology, imaging scans.
Pharmacy sales: Revenue from medicines dispensed within the hospital.
Other services: Emergency care, health check-ups, etc.
Industry
The Indian hospital and healthcare services industry is large and growing, characterized by increasing demand for quality healthcare. It is highly fragmented, with a mix of large corporate hospital chains, regional players, single-site hospitals, and public sector hospitals. KMC Speciality Hospitals likely positions itself as a provider of specialized medical care, competing on the basis of medical expertise, technology, and patient outcomes within its operating regions. It would face competition from both larger national chains with deeper pockets and local standalone hospitals.
MOAT
Brand & Reputation: A strong local or regional brand built on clinical excellence and patient trust in specific specialties can create a durable advantage.
Doctor Relationships: Long-standing relationships with leading doctors and specialists, who often attract patient flow.
Specialized Expertise/Technology: Investment in advanced medical technology and highly specialized departments (e.g., oncology, cardiology, neurosurgery) can differentiate it.
Local Network Effects: Established presence and referral networks within its operating geographies.
Switching Costs: While not always high, for critical or ongoing specialty treatments, patients face high implicit switching costs.
Growth Drivers
Rising Healthcare Demand: Driven by a growing and aging population, increasing prevalence of chronic diseases, and higher health awareness.
Increasing Health Insurance Penetration: Expanding coverage by both government and private insurance schemes makes healthcare more accessible and affordable.
Higher Disposable Incomes: Leading to increased willingness and ability to spend on quality private healthcare.
Medical Tourism: India's potential as a medical tourism destination for certain high-end procedures attracts international patients.
Technological Advancement: Adoption of new medical technologies and procedures allows for expansion of services and improved outcomes.
Expansion & Capacity Addition: Organic growth through increasing bed capacity, adding new specialties, or inorganic growth through acquisitions.
Risks
Regulatory & Pricing Pressure: Government interventions like price caps on medical procedures, drugs, or medical devices can impact profitability.
Talent Attrition: Shortage and high attrition rates of skilled medical professionals (doctors, nurses, technicians) leading to higher salary costs.
Intense Competition: Fierce competition from other private players, including large hospital chains expanding their footprint, leading to pricing pressures and challenges in patient acquisition.
Capital Expenditure: Hospitals are highly capital-intensive businesses requiring significant investment in infrastructure, equipment, and technology.
Medical Malpractice & Litigation: Risks associated with medical errors and subsequent legal liabilities.
Economic Downturns: Reduced discretionary spending on healthcare during economic slowdowns, impacting elective procedures.
Management & Ownership
As a publicly listed company, KMC Speciality Hospitals (India) Ltd. would have a mix of promoter shareholding, institutional investors, and public shareholders. In India, many hospital chains originate from entrepreneurial or physician-led initiatives, which often translates into a promoter-driven management culture focused on operational execution and clinical outcomes. The management would be responsible for strategic growth, operational efficiency, regulatory compliance, and maintaining clinical standards.
Outlook
The Indian healthcare sector is poised for substantial long-term growth driven by fundamental demographic tailwinds, rising incomes, and increasing health insurance coverage. KMC Speciality Hospitals, as a player in this sector, is well-positioned to benefit from these trends, especially given its focus on specialized care which often commands higher margins. However, the company faces inherent challenges including intense competition, the need for continuous capital investment in technology and infrastructure, and potential regulatory interventions on pricing. Success will depend on its ability to effectively manage costs, attract and retain top medical talent, maintain a strong clinical reputation, and strategically expand its service offerings and geographical footprint while navigating the dynamic regulatory landscape.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 45 | 53 | 56 | 61 | 61 | 67 | 75 | 82 | 82 | 92 |
| Other Income | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Total Income | 46 | 54 | 57 | 63 | 62 | 67 | 76 | 83 | 84 | 94 |
| Total Expenditure | 33 | 40 | 44 | 45 | 46 | 50 | 54 | 57 | 56 | 63 |
| Operating Profit | 13 | 14 | 13 | 17 | 16 | 17 | 22 | 26 | 28 | 30 |
| Interest | 0 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 3 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 9 | 7 | 5 | 10 | 9 | 10 | 15 | 18 | 20 | 22 |
| Provision for Tax | 2 | 2 | 1 | 3 | 4 | 2 | 4 | 5 | 5 | 6 |
| Profit After Tax | 7 | 6 | 4 | 8 | 5 | 8 | 11 | 14 | 15 | 17 |
| Adjustments | -0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 |
| Profit After Adjustments | 7 | 6 | 4 | 8 | 5 | 8 | 11 | 14 | 15 | 17 |
| Adjusted Earnings Per Share | 0.4 | 0.3 | 0.2 | 0.5 | 0.3 | 0.5 | 0.7 | 0.8 | 0.9 | 1 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 43 | 55 | 71 | 82 | 96 | 103 | 136 | 156 | 177 | 232 | 306 | 331 |
| Other Income | 1 | 0 | 0 | 2 | 1 | 3 | 2 | 3 | 4 | 3 | 5 | 6 |
| Total Income | 44 | 55 | 71 | 84 | 98 | 105 | 138 | 159 | 181 | 235 | 311 | 337 |
| Total Expenditure | 35 | 42 | 56 | 66 | 75 | 80 | 99 | 114 | 130 | 174 | 218 | 230 |
| Operating Profit | 9 | 13 | 15 | 18 | 23 | 25 | 40 | 45 | 51 | 61 | 94 | 106 |
| Interest | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 10 | 9 | 8 |
| Depreciation | 3 | 3 | 4 | 4 | 5 | 6 | 7 | 8 | 9 | 19 | 22 | 22 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 4 | 8 | 10 | 12 | 17 | 18 | 32 | 36 | 41 | 32 | 63 | 75 |
| Provision for Tax | 1 | 3 | 3 | 4 | 5 | 5 | 8 | 9 | 10 | 10 | 16 | 20 |
| Profit After Tax | 3 | 5 | 7 | 9 | 12 | 13 | 24 | 27 | 30 | 21 | 47 | 57 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 3 | 5 | 7 | 9 | 12 | 13 | 24 | 27 | 30 | 21 | 47 | 57 |
| Adjusted Earnings Per Share | 0.2 | 0.3 | 0.4 | 0.5 | 0.7 | 0.8 | 1.5 | 1.6 | 1.9 | 1.3 | 2.9 | 3.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 32% | 25% | 24% | 22% |
| Operating Profit CAGR | 54% | 28% | 30% | 26% |
| PAT CAGR | 124% | 20% | 29% | 32% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 160% | 24% | 19% | 31% |
| ROE Average | 25% | 21% | 24% | 25% |
| ROCE Average | 27% | 23% | 26% | 28% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 13 | 24 | 30 | 39 | 51 | 63 | 87 | 114 | 144 | 164 | 210 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 6 | 3 | 10 | 8 | 6 | 26 | 20 | 40 | 64 | 72 | 61 |
| Other Non-Current Liabilities | 0 | -5 | -4 | -3 | 11 | 18 | 26 | 38 | 51 | 60 | 82 |
| Total Current Liabilities | 10 | 10 | 12 | 12 | 12 | 13 | 20 | 23 | 46 | 38 | 43 |
| Total Liabilities | 29 | 33 | 49 | 56 | 80 | 120 | 152 | 214 | 305 | 335 | 397 |
| Fixed Assets | 23 | 24 | 36 | 36 | 39 | 74 | 75 | 84 | 205 | 247 | 247 |
| Other Non-Current Assets | 4 | 4 | 4 | 8 | 23 | 20 | 34 | 78 | 66 | 54 | 68 |
| Total Current Assets | 3 | 4 | 8 | 13 | 18 | 26 | 42 | 52 | 34 | 33 | 81 |
| Total Assets | 29 | 33 | 49 | 56 | 80 | 120 | 152 | 214 | 305 | 335 | 397 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 1 | 0 | 2 | 1 | 2 | 2 | 2 | 5 | 9 |
| Cash Flow from Operating Activities | 6 | 10 | 12 | 16 | 11 | 26 | 29 | 32 | 38 | 58 | 79 |
| Cash Flow from Investing Activities | -1 | -4 | -19 | -9 | -8 | -43 | -29 | -48 | -56 | -51 | -17 |
| Cash Flow from Financing Activities | -5 | -5 | 6 | -5 | -4 | 18 | -1 | 16 | 20 | -2 | -21 |
| Net Cash Inflow / Outflow | -0 | 1 | -1 | 1 | -1 | 1 | -0 | 0 | 3 | 4 | 41 |
| Closing Cash & Cash Equivalent | 0 | 1 | 0 | 2 | 1 | 2 | 2 | 2 | 5 | 9 | 50 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.2 | 0.33 | 0.41 | 0.53 | 0.72 | 0.78 | 1.45 | 1.64 | 1.86 | 1.31 | 2.87 |
| CEPS(Rs) | 0.4 | 0.52 | 0.64 | 0.79 | 1.02 | 1.16 | 1.86 | 2.11 | 2.43 | 2.48 | 4.19 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 0.82 | 1.47 | 1.86 | 2.4 | 3.11 | 3.88 | 5.32 | 6.96 | 8.8 | 10.08 | 12.9 |
| Core EBITDA Margin(%) | 18.89 | 22.76 | 20.27 | 19.8 | 22.21 | 22.25 | 27.38 | 26.51 | 26.63 | 24.76 | 28.85 |
| EBIT Margin(%) | 13.38 | 17.15 | 15.26 | 16.69 | 18.54 | 18.73 | 24.31 | 23.83 | 23.78 | 17.97 | 23.52 |
| Pre Tax Margin(%) | 9.53 | 14.57 | 13.87 | 14.99 | 17.36 | 17.58 | 23.59 | 23.11 | 22.89 | 13.65 | 20.61 |
| PAT Margin (%) | 7.55 | 9.77 | 9.41 | 10.46 | 12.21 | 12.45 | 17.44 | 17.13 | 17.15 | 9.25 | 15.28 |
| Cash Profit Margin (%) | 15.26 | 15.59 | 14.88 | 15.57 | 17.35 | 18.46 | 22.23 | 22.04 | 22.35 | 17.44 | 22.37 |
| ROA(%) | 10.63 | 17.14 | 16.3 | 16.4 | 17.24 | 12.81 | 17.48 | 14.59 | 11.7 | 6.7 | 12.78 |
| ROE(%) | 27.24 | 28.6 | 24.43 | 24.78 | 26.17 | 22.42 | 31.61 | 26.65 | 23.63 | 13.92 | 24.94 |
| ROCE(%) | 23.92 | 34.73 | 28.63 | 29.11 | 33.09 | 25.85 | 32.44 | 27.32 | 22.54 | 18.01 | 27.25 |
| Receivable days | 11.65 | 10.83 | 10.74 | 9.23 | 7.27 | 8.28 | 8.17 | 9.27 | 9.02 | 8.16 | 7.96 |
| Inventory Days | 5.79 | 4.33 | 3.49 | 3.58 | 5.99 | 7.07 | 4.86 | 4.86 | 4.45 | 4.37 | 4.41 |
| Payable days | 155.97 | 129.77 | 128.17 | 143.12 | 127.26 | 106.85 | 94.22 | 93.91 | 87.87 | 105.29 | 98.13 |
| PER(x) | 39.98 | 39.63 | 44.01 | 29.22 | 17.39 | 27.82 | 38.25 | 35.16 | 43.57 | 46.73 | 27.48 |
| Price/Book(x) | 9.59 | 8.83 | 9.63 | 6.44 | 4.03 | 5.61 | 10.46 | 8.27 | 9.22 | 6.09 | 6.1 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 3.25 | 3.97 | 4.3 | 3.1 | 2.1 | 3.55 | 6.62 | 6.06 | 7.75 | 4.64 | 4.25 |
| EV/Core EBITDA(x) | 15.43 | 17.28 | 20.74 | 14.25 | 8.87 | 14.37 | 22.76 | 21.09 | 26.74 | 17.73 | 13.9 |
| Net Sales Growth(%) | 17.27 | 28.81 | 28.89 | 16.4 | 16.92 | 6.71 | 32.58 | 14.47 | 13.75 | 30.72 | 32.03 |
| EBIT Growth(%) | 165.58 | 65.12 | 14.64 | 27.36 | 29.88 | 7.79 | 72.1 | 12.21 | 13.53 | -1.23 | 72.78 |
| PAT Growth(%) | 2493.79 | 66.61 | 24.24 | 29.4 | 36.42 | 8.83 | 85.66 | 12.49 | 13.83 | -29.47 | 118.11 |
| EPS Growth(%) | 2493.42 | 66.57 | 24.25 | 29.39 | 36.42 | 8.83 | 85.66 | 12.49 | 13.83 | -29.47 | 118.1 |
| Debt/Equity(x) | 0.77 | 0.26 | 0.48 | 0.26 | 0.15 | 0.43 | 0.31 | 0.39 | 0.5 | 0.5 | 0.34 |
| Current Ratio(x) | 0.31 | 0.41 | 0.68 | 1.01 | 1.43 | 2.08 | 2.18 | 2.3 | 0.72 | 0.88 | 1.9 |
| Quick Ratio(x) | 0.24 | 0.35 | 0.63 | 0.94 | 1.25 | 1.94 | 2.08 | 2.2 | 0.68 | 0.78 | 1.81 |
| Interest Cover(x) | 3.47 | 6.64 | 11.01 | 9.8 | 15.67 | 16.33 | 33.73 | 32.93 | 26.65 | 4.16 | 8.09 |
| Total Debt/Mcap(x) | 0.08 | 0.03 | 0.05 | 0.04 | 0.04 | 0.08 | 0.03 | 0.05 | 0.05 | 0.08 | 0.06 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 |
| FII | 0 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0.02 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 25 | 25 | 25 | 25 | 24.99 | 25 | 25 | 25 | 25 | 24.98 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 12.23 | 12.23 | 12.23 | 12.23 | 12.23 | 12.23 | 12.23 | 12.23 | 12.23 | 12.23 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 4.08 | 4.08 | 4.08 | 4.08 | 4.08 | 4.08 | 4.08 | 4.08 | 4.08 | 4.07 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16.31 | 16.31 | 16.31 | 16.31 | 16.31 | 16.31 | 16.31 | 16.31 | 16.31 | 16.31 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +32% | +25% | +24% | +22% |
| Operating Profit CAGR | +54% | +28% | +30% | +26% |
| PAT CAGR | +124% | +20% | +29% | +32% |
| Share Price CAGR | +160% | +24% | +19% | +31% |
| ROE Average | +25% | +21% | +24% | +25% |
| ROCE Average | +27% | +23% | +26% | +28% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 |
| FII | 0 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0.02 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 25 | 25 | 25 | 25 | 24.99 | 25 | 25 | 25 | 25 | 24.98 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 12.23 | 12.23 | 12.23 | 12.23 | 12.23 | 12.23 | 12.23 | 12.23 | 12.23 | 12.23 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 4.08 | 4.08 | 4.08 | 4.08 | 4.08 | 4.08 | 4.08 | 4.08 | 4.08 | 4.07 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16.31 | 16.31 | 16.31 | 16.31 | 16.31 | 16.31 | 16.31 | 16.31 | 16.31 | 16.31 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.